Chemistry:Doxercalciferol
From HandWiki
| |
| Names | |
|---|---|
| IUPAC name
(1S,3R,5Z,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraene-1,3-diol
| |
| Other names
1-Hydroxyergocalciferol; 1-Hydroxyvitamin D2; 1α-Hydroxyergocalciferol; 1α-Hydroxyvitamin D2; Hectorol; TSA 840
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C28H44O2 | |
| Molar mass | 412.658 g·mol−1 |
| Pharmacology | |
| 1=ATC code }} | H05BX03 (WHO) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
 verify (what is   ?)
| |
| Infobox references | |
Tracking categories (test):
Doxercalciferol (or 1-hydroxyergocalciferol, trade name Hectorol) is drug for secondary hyperparathyroidism and metabolic bone disease.[1] It is a synthetic analog of ergocalciferol (vitamin D2). It suppresses parathyroid synthesis and secretion.[2]
Docercalciferol is the vitamin D2 analogue of alfacalcidol.[3] It undergoes 25-hydroxylation in the liver to become the active ercalcitriol, without the involvement of kidneys.[4]
References
- ↑ Sprague S M; Ho L T (2002). "Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient". Clinical Nephrology 58 (2): 155–160. doi:10.5414/cnp58155. PMID 12227689.
- ↑ "Doxercalciferol". Drugs.com. https://www.drugs.com/ppa/doxercalciferol.html.
- ↑ Upton, R. A.; Knutson, J. C.; Bishop, C. W.; LeVan, L. W. (1 April 2003). "Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone". Nephrology Dialysis Transplantation 18 (4): 750–758. doi:10.1093/ndt/gfg030. PMID 12637645.
- ↑ "HECTOROL INJECTION (doxercalciferol)". https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021027s012lbl.pdf. Retrieved 21 April 2018.
 |  |
